HRR Mutation Testing in mPC
How might advances in testing for homologous recombination repair (HRR) gene mutations benefit your patients with metastatic castration-resistant prostate cancer (mCRPC)? This Learning Zone provides a range of resources to help you put new innovations into practice, and identify patients who may be eligible for life-prolonging treatments, including:
- An overview of the prognostic and predictive value of HRR mutations
- Barriers to equitable testing
- Highlights from ASCO GU 2025, with Professor Karim Fazazi
- Coming soon: The patient’s perspective and expert insights to help optimize patient care, and case studies on interpretation of HRR mutation test results
- Coming soon: Interview with Professor Ashish M Kamat on the key takeaways from EAU 2025, and expert coverage of the 2025 ASCO Annual Meeting and ESMO Congress 2025
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event